Merck and Evotec strike CRISPR licensing deal

Merck has agreed to license its CRISPR gene-editing technology to German biotech company Evotec.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USITC investigates grey market IVF products

14 April 2020 The US International Trade Commission is investigating ‘grey market’ in vitro fertilisation products intended for the Turkish market, following a trademark complaint from German pharmaceutical company Merck KGaA.

Big Pharma

EU General Court sides with Merck in TM opposition

21 November 2019 A German individual has lost an appeal before the tribunal of the EU General Court, after his trademark registration was opposed by Merck.

Americas

Sigma-Aldrich submits CRISPR petition at USPTO

23 July 2019 Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Merck and Evotec strike CRISPR licensing deal

More on this story

Editor's picks

Editor's picks

More features